{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:09:29Z","timestamp":1774922969865,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clinre.2021.101675","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:14:53Z","timestamp":1616087693000},"page":"101675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of obeticholic acid in liver disease\u2014A systematic review and meta-analysis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1240-1675","authenticated-orcid":false,"given":"Anand V.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4137","authenticated-orcid":false,"given":"Harsh Vardhan","family":"Tevethia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-7737","authenticated-orcid":false,"given":"Roberto","family":"Candia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-4148","authenticated-orcid":false,"given":"Madhumita","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-0496","authenticated-orcid":false,"given":"D. Nageshwar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagaraja Rao","family":"Padaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2021.101675_bib0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0010","first-page":"40","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the Holy Grail","volume":"9","author":"Sharma","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2021.101675_bib0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2021.101675_bib0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clinre.2021.101675_bib0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2021.101675_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104333","article-title":"Semisynthetic bile acids: a new therapeutic option for metabolic syndrome","volume":"146","author":"Lazarevi\u0107","year":"2019","journal-title":"Pharmacol Res"},{"issue":"17","key":"10.1016\/j.clinre.2021.101675_bib0045","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6Alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"issue":"17\u201318","key":"10.1016\/j.clinre.2021.101675_bib0060","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov Today"},{"issue":"9972","key":"10.1016\/j.clinre.2021.101675_bib0065","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinre.2021.101675_bib0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2021.101675_bib0080","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.clinre.2021.101675_bib0085","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2021.101675_bib0090","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.clinre.2021.101675_bib0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clinre.2021.101675_bib0100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.clinre.2021.101675_bib0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0110","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"10215","key":"10.1016\/j.clinre.2021.101675_bib0115","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0120","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Al-Dury","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13974","article-title":"Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis","volume":"39","author":"Chalasani","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2021.101675_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0155","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/liv.14429","article-title":"Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis","volume":"40","author":"Par\u00e9s","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.clinre.2021.101675_bib0160","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0165","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2021.101675_bib0170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2021.101675_bib0175","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.clinre.2021.101675_bib0180","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep4.1173","article-title":"A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale","volume":"2","author":"Levy","year":"2018","journal-title":"Hepatol Commun."},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.clinre.2021.101675_bib0190","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12681","article-title":"Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers","volume":"18","author":"Pencek","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13531","article-title":"Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD","volume":"38","author":"Nobili","year":"2018","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.clinre.2021.101675_bib0200","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.clinre.2021.101675_bib0210","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.clinre.2021.101675_bib0215","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2021.101675_bib0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.clinre.2021.101675_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.clinre.2021.101675_bib0230","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2021.101675_bib0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"issue":"Suppl. 1: s3-105","key":"10.1016\/j.clinre.2021.101675_bib0240","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.5604\/01.3001.0010.5497","article-title":"Bile acids in cholestasis and its treatment","volume":"16","author":"Arab","year":"2017","journal-title":"Ann Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2021.101675_bib0245","first-page":"1615","article-title":"Pathogenesis of primary biliary cirrhosis","volume":"56","author":"Jones","year":"2007","journal-title":"Gut"},{"issue":"24","key":"10.1016\/j.clinre.2021.101675_bib0250","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0030-1253225","article-title":"Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis","volume":"30","author":"Wagner","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.clinre.2021.101675_bib0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3748\/wjg.v7.i2.157","article-title":"Hepatocellular transport proteins and their role in liver disease","volume":"7","author":"Stanca","year":"2001","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2021.101675_bib0265","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:18:21Z","timestamp":1755083901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740121000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2210740121000541"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101675","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of obeticholic acid in liver disease\u2014A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101675"}}